Recipient cytotoxic T lymphocyte antigen-4 +49 G/G genotype is associated with reduced incidence of hepatitis B virus recurrence after liver transplantation among Chinese patients

Liver International

Volumn 27, Issue 9, 2007, Pages 1202-1208

  Jiang, Zhijun ^a   Feng, Xiaoning ^a   Zhang, Wu ^a   Gao, Feng ^a   Ling, Qi ^a   Zhou, Lin ^a   Xie, Haiyang ^a   Chen, Qixing ^a   Zheng, Shusen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CTLA 4; HBV recurrence; Liver transplantation; SNP

Indexed keywords

CD86 ANTIGEN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GENOMIC DNA; GLYCINE; HEPATITIS B ANTIBODY; LAMIVUDINE; METHYLPREDNISOLONE; TACROLIMUS; VIRUS DNA;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG DOSE COMPARISON; FEMALE; GENE FREQUENCY; GENOTYPE; GRAFT REJECTION; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HETEROZYGOTE; HUMAN; INCIDENCE; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RECIPIENT; REINFECTION; RISK FACTOR; RISK REDUCTION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIGENS, CD; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECURRENCE;

EID: 35148869631     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01553.x     Document Type: Article

References (37)

1. Villamil FG. Hepatitis B: Progress in the last 15 years. Liver Transpl 2002; 8: S59-66.
2. Trautwein C. Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation. J Hepatol 2004; 41: 362-9.
3. de Reuver P, Pravica V, Hop W, et al. Recipient CTLA-4 +49 G/G genotype is associated with reduced incidence of acute rejection after liver transplantation. Am J Transplant 2003; 3: 1587-94.
4. Matsushita M, Tsuchiya N, Oka T, Yamane A, Tokunaga K. New polymorphisms of human CD80 and CD86: Lack of association with rheumatoid arthritis and systemic lupus erythematosus. Genes Immun 2000; 1: 428-34.
5. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA-4 with susceptibility to autoimmune disease. Nature 2003; 29: 506-11.
6. Kavvoura FK, Ioannidis JP. CTLA-4 gene polymorphisms and susceptibility to type 1 diabetes mellitus: A HuGE Review and meta-analysis. Am J Epidemiol 2005; 162: 3-16.
7. Goswami R, Gupta N, Ray D, et al. Polymorphisms at +49A/G and CT60 sites in the 3′ UTR of the CTLA-4 gene and APECED-related AIRE gene mutations analysis in sporadic idiopathic hypoparathyroidism. Int J Immunogenet 2005; 32: 393-400.
8. Wu LM, Xu X, Zheng SS. Hepatitis B virus reinfection after liver transplantation: Related risk factors and perspective. Hepatobiliary Pancreat Dis Int 2005; 4: 502-8.
9. Thio CL, Mosbruger TL, Kaslow RA, et al. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 2004; 78: 11258-62.
10. Yee LJ, Perez KA, Tang J, et al. Association of CTLA-4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis 2003; 187: 1264-71.
11. Marinos G, Rossol S, Carucci P, et al. Immunopathogenesis of hepatitis B virus recurrence after liver transplantation. Transplantation 2000; 69: 559-68.
12. Thung SN. Histologic findings in recurrent HBV. Liver Transpl 2006; 12: S50-3.
13. Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-8.
14. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002; 420: 502-7.
15. Xu D, Fu J, Jin L, et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739-47.
16. Pontesilli O, van Nunen AB, van Riel D, et al. Hepatitis B virus-specific T cell response in chronic hepatitis B patients treated with lamivudine and interferon-alpha. Liver Int 2004; 24: 308-15.
17. Stoop JN, van der Molen RG, Baan CC, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-8.
18. Roh S, Kim K. Overcoming tolerance in hepatitis B virus transgenic mice: a possible involvement of regulatory T cells. Microbiol Immunol 2003; 47: 453-60.
19. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225-52.
20. Sun J, Tumurbaatar B, Jia J, et al. Parenchymal expression of CD86/B7.2 contributes to hepatitis C virus-related liver injury. J Virol 2005; 79: 10730-9.
21. Shevach EM. CD4+CD25+suppressor T cells: More questions than answers. Nat Rev Immunol 2002; 2: 389-400.
22. Sahin M, Erdogan MF, Erdogan G. Cytotoxic T lymphocyte-associated molecule-4 polymorphisms in Turkish Graves' disease patients and association with probability of remission after antithyroid therapy. Eur J Intern Med 2005; 16: 352-5.
23. Pawlak E, Kochanowska IE, Frydecka I, Kielbinski M, Potoczek S, Bilinska M. The soluble CTLA-4 receptor: A new marker in autoimmune diseases. Arch Immunol Ther Exp (Warsz) 2005; 53: 336-41.
24. Ueda Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA-4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-11.
25. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25+CD4+regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192: 303-10.
26. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity? Genes Immun 2000; 1: 170-84.
27. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000; 165: 6606-11.
28. Maurer M, Loserth S, Kolb-Maurer A, et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene (exon 1+49) alters T-cell activation. Immunogenetics 2002; 54: 1-8.
29. Anjos S, Nguyen A, Ounissi-Benkalha H, et al. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem 2002; 277: 46478-84.
30. Kuhns MS, Epshteyn V, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. Proc Natl Acad Sci USA 2000; 97: 12711-6.
31. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10: S74-85.
32. Neff GW, O'Brien CB, Nery J, et al. Outcomes in liver transplant recipients with hepatitis B virus: Resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2005; 11: 1372-8.
33. Seehofer D, Rayes N, Steinmuller T, et al. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. Liver Transpl 2001; 7: 976-82.
34. Marin LA, Moya-Quiles MR, Miras M, et al. Evaluation of CD86 gene polymorphism at +1057 position in liver transplant recipients. Transpl Immunol 2005; 15: 69-74.
35. Lee CS, Lee YJ, Liu HF, et al. Association of CTLA-4 gene A-G polymorphism with rheumatoid arthritis in Chinese. Clin Rheumatol 2003; 22: 221-4.
36. Mohammad Alizadeh AH, Hajilooi M, Ranjbar M, et al. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to chronic hepatitis B. World J Gastroenterol 2006; 28: 630-5.
37. Holt CD, Millis JM, Busuttil RW. Role of liver transplantation in patients with hepatitis B infection. Clin Transplant 1995; 9: 269-76.